Bond Cliff

Main Menu

  • Home
  • Economic integration
  • Price index
  • Covariance
  • Labor augmenting
  • Fund

Bond Cliff

Header Banner

Bond Cliff

  • Home
  • Economic integration
  • Price index
  • Covariance
  • Labor augmenting
  • Fund
Covariance
Home›Covariance›Effect of low-dose statins in addition to standard treatment on cerebral perfusion and neurocognitive performance in patients with major depressive disorder

Effect of low-dose statins in addition to standard treatment on cerebral perfusion and neurocognitive performance in patients with major depressive disorder

By Susan Weiner
January 30, 2022
0
0

This article was originally published here

Neuropsychobiology. 2022 January 28:1-15. doi: 10.1159/000521104. Online ahead of print.

ABSTRACT

Introduction: Major depressive disorder (MDD) is a prevalent condition that has a well-known association with ischemic cardiomyopathy, probably explained by an inflammatory mediating mechanism. Statins, in addition to reducing cholesterol production, have pleiotropic effects, including anti-inflammatory activity. The aim was to assess the effect of statins as an adjunct to standard treatment on mood state, cerebral perfusion and neurocognitive performance in MDD.

METHODS: We studied 20 patients with CT with single photon emission brain computed tomography and Cambridge Automated Neuropsychological Testing Battery (CANTAB), half-randomised to receive rosuvastatin 10 mg or placebo, in addition to treatment with selective serotonin reuptake inhibitors (SSRIs) and reassessed 3 months later. Images were compared using statistical parametric mapping; clinical scores (Hamilton Depression Score with 17 items and Beck’s Depression Inventory) as well as neurocognitive parameters were applied as covariances (CoV) to estimate changes in regional cerebral blood flow (rCBF) with both therapies.

RESULTS: Clinical scores decreased in both groups (p=0.0001); Beck showed a greater decrease with statins. We observed significant changes in rCBF expressed as larger voxel clusters (p

CONCLUSION: Short-term use of low-dose statins in MDD patients on SSRIs results in significant changes in rSCr in key mood-associated domains with improved neurocognitive performance. These discoveries, although demonstrated on a small sample, could open up a new therapeutic tool in the global management of this disorder.

PMID:35093946 | DO I:10.1159/000521104

Related posts:

  1. How to improve collaborative filtering with dimensionality reduction?
  2. Increasing the Acceptability and Expected Outcomes of Internet-Based Cognitive Behavioral Therapy During the COVID-19 Pandemic
  3. Urban emissions, air quality and heat: CSU researchers receive more than $ 2.2 million
  4. Prototype radar will detect areas of increased greenhouse gas emissions in the Florida Everglades

Categories

  • Covariance
  • Economic integration
  • Fund
  • Labor augmenting
  • Price index
  • TERMS AND CONDITIONS
  • Privacy Policy